Brief: Surrozen Initiates Dosing In Phase 1 Clinical Trial Of Szn-043 For Severe Alcoholic Hepatitis
13/06/2022 13:24
June 13 (Reuters) - Surrozen Inc SRZN.O :
* SURROZEN INITIATES DOSING IN PHASE 1 CLINICAL TRIAL OF
SZN-043
FOR SEVERE ALCOHOLIC HEPATITIS
Source text for Eikon: ID:nGNX1FlFkJ
Further company coverage: SRZN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Surrozen
See all newsBrief: Surrozen Announces Closing Of Second Tranche Of March 2025 Private Placement For $95.1 Million
Surrozen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Surrozen Q2 Operating Income USD -10.37 Million
Surrozen, Inc. expected to post a loss of $1.29 a share - Earnings Preview
Brief: Surrozen Q1 EPS USD -11.65